Hormone replacement therapy in gynecologic cancer survivors: Why not?

Gynecologic Oncology

Volumn 122, Issue 2, 2011, Pages 447-454

  Ibeanu, Okechukwu ^a   Modesitt, Susan C ^b   Ducie, Jennifer ^a   Von Gruenigen, Vivian ^c   Agueh, Modupe ^a   Fader, Amanda Nickles ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c AKRON CITY HOSPITAL   (United States)

Author keywords

Gynecologic cancer survivor; Hormone replacement therapy; Menopause; Quality of life

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; ESTROGEN; FLUOXETINE; PAROXETINE; VENLAFAXINE;

CANCER RISK; CANCER SURVIVOR; ENDOMETRIUM CANCER; GENE MUTATION; GYNECOLOGIC CANCER; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HORMONE SUBSTITUTION; HUMAN; MENOPAUSE; MOOD DISORDER; OSTEOPOROSIS; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; UTERINE CERVIX CANCER; VAGINAL DRYNESS; VASOMOTOR DISORDER;

ESTROGEN REPLACEMENT THERAPY; FEMALE; GENES, BRCA1; GENES, BRCA2; GENITAL NEOPLASMS, FEMALE; HUMANS; LYNCH SYNDROME II; MENOPAUSE; NEOPLASM RECURRENCE, LOCAL; QUALITY OF LIFE; SURVIVORS;

EID: 79960451602     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.03.012     Document Type: Review

References (72)

1. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics 2010 Sep-Oct CA Cancer J Clin 60 5 2010 277 300
2. J.D. Wright Safety of ovarian preservation in premenopausal women with endometrial cancer J Clin Oncol 27 8 Mar. 10 2009 1214 1219 Epub 2009 Jan 26.
3. C. Burger, Van Leeuwen, and F. Scheele Hormone replacement therapy in women treated for gynaecologic malignancy Maturitas 32 1999 69 76 (Pubitemid 29295411)
4. P. Belchetz Hormonal treatment of post-menopausal women N Engl J Med 330 1994 1062 1065
5. N. Woods, and E. Mitchell Symptoms during the perimenopause: prevalence, severity, trajectory, and significance in women's lives Am J Med 118 2005 14 18
6. L. Hinds, and J. Price Menopause, hormone replacement and gynaecologic cancers Menopause Int 16 2010 89 93
7. W. Parker, M. Broader, and E. Chang Ovarian conservation at the time of hysterectomy and long-term health outcomes in the Nurses Health Study Obstet Gynecol 113 5 2009 1027 1037
8. S. Domchek, T. Friebel, and C. Singer Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality JAMA 304 9 2010 967 975
9. L. Cohen Cancer treatment and the ovary. The effects of chemotherapy and radiation Ann NY Acad Sci 1135 2008 123 125 (Pubitemid 351862136)
10. D. Green, C. Sklar, J. Boice, J. Mulvihill, J. Whitton, and M. Stovall Ovarian failure and reproductive outcomes after childhood cancer treatment: results from the Childhood Cancer Survivor Study J Clin Oncol 27 2009 2374 2381
11. C. Sklar Maintenance of ovarian function and risk of premature menopause related to cancer treatment J Natl Cancer Inst Monogr 34 2005 25 27
12. W.H. Wallace, A.B. Thomson, and T.W. Kelsey The radiosensitivity of the human oocyte Hum Reprod 18 2003 117 121 (Pubitemid 36138861)
13. A. Hershlag, and M. Schuster Return of fertility after autologous stem cell transplantation Fertil Steril 77 2002 419 423
14. C. Farquhar, J. Marjoribanks, A. Lethaby, J.A. Suckling, and Q. Lamberts Long term hormone therapy for perimenopausal and postmenopausal women Cochrane Database Syst Rev 2 2009 CD004143
15. S. Hulley, D. Grady, and T. Bush Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women JAMA 280 1998 605 613 (Pubitemid 28502636)
16. D. Grady, D. Herrington, and V. Bittner Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study follow-up (HERS II) JAMA 288 2002 49 57 (Pubitemid 34705518)
17. Writing Group for the Women's Health Initiative Investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women JAMA 288 2002 321 333
18. The Women's Health Initiative Steering Committee Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative Randomized Controlled Trial JAMA 291 2004 1701 1712
19. T. Rebbeck, N. Kauff, and S. Domchek Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA 2 mutation carriers J Natl Cancer Inst 101 2009 80 87
20. Finch A, Metcalfe KA, Chiang JK, Elit L, McLauglin J, Springate C, et al. The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation. Gynecol Oncol, Article in Press, 2010
21. K. Armstrong, J. Schwartz, T. Randall, S. Rubin, and B. Weber Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis J Clin Oncol 22 2004 1045 1054 (Pubitemid 41095037)
22. T. Rebbeck, T. Friebel, and T. Wagner Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA 1 and BRCA 2 mutation carriers: the PROSE Study Group J Clin Oncol 23 2005 7804 7810 (Pubitemid 46657377)
23. N. Kauff, S. Domchek, and T. Friebel Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multi-center, prospective study J Clin Oncol 26 2008 1331 1337
24. A. Eisen Lubinski J., Moller P., et al. Hormone therapy and the risk of breast cancer in BRCA 1 mutation carriers J Natl Cancer Inst 100 2008 1361 1367
25. American College of Obstetrics and Gynecology Bulletin #89. Elective and risk-reducing salpingo-oophorectomy Obstet Gynecol 111 2008 231 241
26. L. Holmberg, and H. Anderson HABITS (hormonal replacement therapy after breast cancer - is it safe?), a randomized comparison: trial stopped Lancet 363 2004 453 455 (Pubitemid 38210063)
27. S. Weissman, C. Bellcross, and C. Bittner Genetic counseling considerations in the evaluation of families for Lynch syndrome. A review J Gene Couns 2010 e-Publication ahead of print.
28. K. Schmeler, H. Lynch, and L. Chen Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome N Engl J Med 354 2006 261 269 (Pubitemid 43113031)
29. A. Ferreira, H. Westers, and A. Albergaria Estrogens, MSI, and Lynch syndrome-associated tumors Biochim Biophys Acta 1796 2 2009 194 200
30. D. Gallup, and R. Stock Adenocarcinoma of the endometrium in women 40 years of age or younger Obstet Gynecol 64 1984 417 420 (Pubitemid 14073467)
31. G. Whitaker, R. Lee, and W. Benson Carcinoma of the endometrium in young women Mil Med 151 1986 25 31
32. W.T. Creasman, D. Henderson, W. Hinshaw, and D.L. Clarke-Pearson Estrogen replacement therapy in the patient treated for endometrial cancer Obstet Gynecol 67 1986 326 330 (Pubitemid 16129969)
33. R. Lee, T. Burke, and R. Park Estrogen replacement therapy following treatment for stage I endometrial carcinoma Gynecol Oncol 36 1990 189 191 (Pubitemid 20061284)
34. K.A. Suriano, M. McHale, C.E. McLaren, K.T. Li, A. Re, and P.J. DiSaia Estrogen replacement therapy in endometrial cancer patients: a matched control study Obstet Gynecol 97 2001 555 560
35. R. Barakat, B. Bundy, N. Spirtos, J. Bell, and R. Mannel Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group study J Clin Oncol 24 2006 587 592 (Pubitemid 46630420)
36. S. Coughlin, A. Giustozzi, S. Smith, and N. Lee A meta-analysis of estrogen replacement therapy and risk of epithelial ovarian cancer J Clin Epidemiol 53 2000 367 375 (Pubitemid 30216475)
37. G. Anderson, H. Judd, and A. Kaunitz Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial JAMA 290 2003 1739 1748 (Pubitemid 37430624)
38. L. Morch, E. Lokkegaard, and A. Andreasen Hormone therapy and ovarian cancer JAMA 302 3 2009 298 305
39. S. Bebar, and M. Ursic-Vrscaj Hormone replacement therapy after epithelial ovarian cancer treatment Eur J Gynecol Oncol 21 2000 192 196 (Pubitemid 30240610)
40. R. Eeles, E. Wiltshaw, I. Fryatt, R. A'Hern, J. Shepherd, and C. Harmer Hormone replacement therapy and survival after surgery for ovarian cancer BMJ 302 1991 262 265
41. F. Guidozzi, and A. Daponte Estrogen replacement therapy for ovarian carcinoma survivors Cancer 86 1999 1013 1018
42. M.P. Schlumbrecht, C.C. Sun, K.N. Wong, R.R. Broaddus, D.M. Gershenson, and D.C. Bodurka Clinicodemographic factors influencing outcomes in patients with low-grade serous ovarian carcinoma Cancer Feb. 11 2011 10.1002/cncr.25929 Epub ahead of print
43. C. Mascarenhas, M. Lambe, R. Belloco, K. Bergfelt, T. Riman, and I. Persson Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival Int J Cancer 119 2006 2907 2915 (Pubitemid 44846244)
44. J. Lacey, L. Brinton, W. Barnes, P. Gravitt, M. Greenberg, and O. Hadjimichael Use of hormone replacement therapy and adenocarcinomas and squamous cell carcinomas of the uterine cervix Gynecol Oncol 77 2000 149 154 (Pubitemid 30217318)
45. J. Martin, R. Hahnel, A. McCartney, and N. De Klerk The influence of estrogen and progesterone receptors on survival in patients with carcinoma of the uterine cervix Gynecol Oncol 23 1986 329 335 (Pubitemid 16129945)
46. K. Bodner, P. Laubichler, O. Kimberger, K. Czerwenka, R. Zeillenger, and B. Bodner-Adler Oestrogen and progesterone receptor expression in patients with adenocarcinoma of the uterine cervix and correlation with various clinicopathological parameters Anticancer Res 30 2010 1341 1346
47. A. Brand, C. Bull, and B. Cakir Vaginal stenosis in patients treated with radiotherapy for carcinoma of the cervix Int J Gynecol Cancer 16 2006 288 293
48. E. Ploch Hormonal replacement therapy in patients after cervical cancer treatment Gynecol Oncol 26 1987 169 177 (Pubitemid 17026675)
49. R. Martin, B. Wheeler, C. Metcalf, and D. Gunnell What was the immediate impact on population health of the recent fall in hormone replacement therapy prescribing in England? Ecological study J Public Health Oxf 2010 e-Publication ahead of print.
50. A.L. Hersh, M.L. Stefanick, and R.S. Stafford National use of postmenopausal hormone therapy: annual trends and response to recent evidence JAMA 291 2004 47
51. J.S. Haas, C.P. Kaplan, E.P. Gerstenberger, and K. Kerlikowske Changes in the use of postmenopausal hormone therapy after publications of clinical trial results Ann Intern Med 140 2004 184
52. V. Stearns, R. Slack, and N. Greep Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial J Clin Oncol 23 2005 6919 6930
53. V. Stearns, K. Beebe, M. Iyengar, and E. Dube Paroxetine controlled release in the treatment of menopausal hot flashes. A randomized controlled trial JAMA 289 2003 2827 2834 (Pubitemid 37430118)
54. M. Evans, E. Pritts, and E. Vittinghoff Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial Obstet Gynecol 105 2005 161 166 (Pubitemid 40189927)
55. C. Loprinzi, R. Levitt, and D. Barton Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group trial N99C7 J Clin Oncol 24 2006 1409 1414 (Pubitemid 46622006)
56. C. Loprinzi, J. Sloan, and E. Perez Phase III evaluation of fluoxetine for treatment of hot flashes J Clin Oncol 20 2002 1578 1583 (Pubitemid 34260538)
57. A. Nedrow, J. Miller, and M. Walker Complementary and alternative therapies for the management of menopause-related symptoms. A systematic evidence review Arch Intern Med 166 2006 1453 1465 (Pubitemid 44125864)
58. K. Newton, D. Buist, and N. Keenan Use of alternative therapies for menopause symptoms: results of a population-based survey Obstet Gynecol 100 2002 18 25 (Pubitemid 34722839)
59. D. McKay, J. Bentley, and R. Grimshaw Complementary and alternative medicine in gynaecologic oncology J Obstet Gynaecol Can 27 2005 562 568
60. C. Mueller, P. Mai, and J. Bucher Complementary and alternative medicine use among women at increased genetic risk of breast and ovarian cancer BMC Compl Alt Med 8 2008 17
61. V.E. von Gruenigen, L.J. White, M.S. Kirven, A.L. Showalter, M.P. Hopkins, and E.L. Jenison A comparison of complementary and alternative medicine use by gynecology and gynecologic oncology patients May-Jun Int J Gynecol Cancer 11 3 2001 205 209 (Pubitemid 32622667)
62. A. Jacobs, U. Wegewitz, and C. Sommerfeld Efficacy of isoflavones in relieving vasomotor menopausal symptoms - a systematic review Mol Nutr Food Res 53 2009 1084 1097
63. F. Borrelli, and E. Ernst Black cohosh (Cimicifuga racemosa) for menopausal symptoms: a systematic review of its efficacy Pharmacol Res 58 2008 8 14
64. S. Frei-Kleiner, W. Schaffner, and V. Rahlfs Cimicifuga racemosa dried ethanolic extract in menopausal disorders: a double-blind placebo-controlled clinical trial Maturitas 51 2005 397 404 (Pubitemid 41019367)
65. S. Reed, K. Newton, and A. LaCroix Vaginal, endometrial, and reproductive hormone findings: randomized, placebo-controlled trial of black cohosh, multibotanical herbs, and dietary soy for vasomotor symptoms: the Herbal Alternatives for Menopause (HALT) study Menopause 15 2008 51 58
66. B. Pockaj, J. Gallagher, and C. Loprinzi Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG trial N01CC J Clin Oncol 24 2006 2836 2841 (Pubitemid 46630583)
67. E. Brink, V. Coxam, and S. Robins Long-term consumption of isoflavone-enriched foods does not affect bone mineral density, bone metabolism, or hormonal status in early postmenopausal women: a randomized, double-blind, placebo controlled study Am J Clin Nutr 87 2008 761 770 (Pubitemid 351364559)
68. J. Allen, D. Becker, and P. Kwiterovich Effect of soy protein-containing isoflavones on lipoproteins in postmenopausal women Menopause 14 2007 106 114 (Pubitemid 46072011)
69. M. Atteritano, H. Marini, and L. Minutoli Effects of the phytoestrogen genistein on some predictors of cardiovascular risk in osteopenic, postmenopausal women: a two-year randomized, double-blind, placebo-controlled study J Clin Endocrinol Metab 92 8 2007 3068 3075 (Pubitemid 47236372)
70. P. Albertazzi, A. Steel, and M. Bottazzi Effect of pure genistein on bone markers and hot flushes Climacteric 8 2005 371 379 (Pubitemid 41617486)
71. C. Atkinson, J. Compston, and N. Day The effects of phytoestrogen isoflavones on bone density in women: a double-blind, randomized, placebo-controlled trial Am J Clin Nutr 79 2004 326 333 (Pubitemid 41095988)
72. V. Unfer, M. Casini, and L. Costabile Endometrial effects of long-term treatment with phytoestrogens: a randomized, double-blind, placebo-controlled study Fertil Steril 82 2004 145 148 (Pubitemid 38968790)